<DOC>
	<DOCNO>NCT02539810</DOCNO>
	<brief_summary>The ANDORRA study , multicenter , prospective , open , randomize , control blind endpoint trial ( PROBE ) compare two treatment strategy ( renal artery stenting + standardize optimized medical treatment [ SOMT ] versus SOMT alone ) 12 month duration patient confirm resistant hypertension ( RH ) angiographically prove grade III unilateral bilateral atherosclerotic renal artery stenosis ( ARAS ) ≥ 60 % .</brief_summary>
	<brief_title>Renal Artery Stenting Patients With Documented Resistant Hypertension Atherosclerotic Renal Artery Stenosis ( ANDORRA )</brief_title>
	<detailed_description>All eligible patient diagnose RH office BP measurements unilateral bilateral ARAS ≥60 % non-invasive test ( CT-angiogram MR-angiogram ) receive standardize optimized triple antihypertensive treatment 4 week . After 4 week , patient confirm RH ABPM ( daytime ABPM ≥ 135 85 mmHg ) clinically significant increase plasma creatinine baseline ( &lt; 30 % ) undergo renal angiogram confirm degree ARAS ≥60 % diameter . Immediately renal angiography , patient undergo flow fractional reserve ( FFR ) measurement . Once FFR measurement do criterion meet , patient randomize angiography room either renal artery stenting + SOMT ( stenting group ) versus SOMT ( control group ) whatever result FFR 1:1 ratio . Both group continue SOMT follow-up . The SOMT prescribe inclusion visit 6 month-visit randomization . After randomization , antihypertensive treatment adapt accord result home BP ( HBP ) monthly visit start 2 month randomization . After 6-month visit , antihypertensive treatment adaptation leave discretion physician charge patient .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Renal Artery Obstruction</mesh_term>
	<mesh_term>Coronary Vasospasm</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>Age : 40 80 Years Men woman Supine office BP ≥ 140 and/or 90 mmHg screen despite stable medication regimen include full tolerate dos 3 antihypertensive treatment different class , include diuretic . Unilateral bilateral ARAS main renal artery ≥60 % diagnosed renal CT angiogram ( MRangiogram contraindication perform CT ) perform year One two functional kidney ( ) ≥ 70 mm poletopole length eGFR ≥ 20 ml/min/1.73 m² ( MDRD formula ) Signed informed consent Social insurance coverage Inclusion criterion renal angiogram procedure : RH confirm daytime ABPM ≥ 135 85 mmHg 1 month treatment SOMT Visit V1 . Inclusion criterion randomization : Unilateral bilateral ARAS main renal artery ≥ 60 % confirm renal angiogram Quantitative Vascular Analysis ( QVA ) Increase plasma creatinine &lt; 30 % 4week SOMT Fibromuscular dysplasia renal artery nonatherosclerotic renal artery stenosis Other secondary form hypertension exclude basis clinical , hormonological and/or image workup Restenosis previous renal angioplasty stenting Only stenosis accessory renal artery supply &lt; 1/2 ipsilateral renal parenchyma Additional indication ARAS stenting ( Malignant hypertension , ≥ 30 % increase plasma creatinine renin angiotensin system ( RAS ) blocker RAS blocker diuretic administration , flash pulmonary edema ) Kidney poletopole length &lt; 70 mm Vascular disease preclude access stenting Abrupt vessel closure dissection diagnostic angiography Contraindication renal artery stenting accord notice use stent eGFR &lt; 20 ml/min/1.73 m² ( MDRD ) History transient ischemic accident ( TIA ) cerebrovascular accident ( CVA ) 3 month prior visit 1 History acute heart failure heart failure ( NYHA class IIIIV ) within 3 month prior visit 1 History myocardial infarction , unstable angina , coronary bypass percutaneous coronary angioplasty 3 month prior visit 1 Abdominal aortic aneurysm indication surgery EVAR ( Endovascular Aneurysm Repair ) Known history cholesterol embolism Brachial circumference ≥ 42 cm Severe contrast medium allergy , amenable pretreatment Allergy aspirin clopidogrel Atrial fibrillation Comorbid condition cause life expectancy ≤ 3 year Unlikely cooperate study and/or poor compliance anticipate investigator Participant affiliate French social security Pregnancy breastfeed Guardianship incapacity</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>